日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies

使用纳米抗体功能化的磁荧光纳米组装体特异性靶向表达间皮素的恶性细胞

Tina Briolay, Judith Fresquet, Damien Meyer, Brigitte Kerfelec, Patrick Chames, Eléna Ishow, Christophe Blanquart

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies

基于纳米抗体的间皮素表达恶性肿瘤快速成像技术,可与阻断治疗性抗体兼容。

Abdennour Benloucif ,Damien Meyer ,Laure Balasse ,Armelle Goubard ,Lucile Danner ,Ahlem Bouhlel ,Rémy Castellano ,Benjamin Guillet ,Patrick Chames ,Brigitte Kerfelec

Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response

抗 NKG2D 单结构域抗体用于调节抗肿瘤免疫反应

Adeline Raynaud, Klervi Desrumeaux, Laurent Vidard, Elise Termine, Daniel Baty, Patrick Chames, Emmanuelle Vigne, Brigitte Kerfelec

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer

基于双特异性抗体的三阴性乳腺癌间皮素靶向方法

Joanie Del Bano, Rémy Florès-Florès, Emmanuelle Josselin, Armelle Goubard, Laetitia Ganier, Rémy Castellano, Patrick Chames, Daniel Baty, Brigitte Kerfelec

Nanobody-CD16 Catch Bond Reveals NK Cell Mechanosensitivity

纳米抗体-CD16 捕获键揭示 NK 细胞机械敏感性

Cristina González, Patrick Chames, Brigitte Kerfelec, Daniel Baty, Philippe Robert, Laurent Limozin

Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer

间皮素特异性配体对三阴性乳腺癌 SPECT 成像的临床前评估

Christopher Montemagno, Sandrine Bacot, Mitra Ahmadi, Brigitte Kerfelec, Daniel Baty, Marlene Debiossat, Audrey Soubies, Pascale Perret, Laurent Riou, Daniel Fagret, Alexis Broisat, Catherine Ghezzi

Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display

掩蔽选择:一种通过噬菌体展示选择针对特定表位和差异表达蛋白的结合物的直接而灵活的方法

Klervi Even-Desrumeaux, Damien Nevoltris, Marie Noelle Lavaut, Karima Alim, Jean-Paul Borg, Stéphane Audebert, Brigitte Kerfelec, Daniel Baty, Patrick Chames

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy

与 FcγRIII 结合的双特异性抗体扩大了适合抗体治疗的 HER2 表达乳腺肿瘤的范围

Marc Turini, Patrick Chames, Pierre Bruhns, Daniel Baty, Brigitte Kerfelec